COMPANY PROFILE

Envisagenics

Leveraging artificial intelligence, high performance computing, and RNA sequencing data to find cures faster than ever before

New York City, United StatesFounded 2014Biotech & Life Sciences

Valuation $100–250M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Envisagenics

An AI-driven biotechnology company focused on RNA splicing therapeutics. Its proprietary SpliceCore® platform uses cloud-based, machine learning algorithms to analyze RNA data, identifying new drug targets and biomarkers.

Read full description

Envisagenics's primary clients are pharmaceutical and biotechnology companies. The company's business model revolves around its SpliceCore platform, which it uses to form strategic partnerships to accelerate the discovery and development of new therapies. It also has an internal pipeline of drug candidates in oncology and neurodegenerative diseases.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: New York City, United States
Employees: 37
Open positions: None listed
Dealroom signal: 61.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Analytics, Biotechnology, Drug Development, Genetics and genomics, Core AI
Technology: Artificial Intelligence, Deep Tech, Machine Learning, Deep Learning, Nanotech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Jun 2024	$25M	$100M	Empire State Development · Bristol-Myers Squibb · Third Kind Venture Capital · Red Cell Partners	↗
SERIES AEquity / VC	May 2023	$0	—	Undisclosed	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Envisagenics website traffic

Latest recorded traffic for Envisagenics is 1.5K monthly website visits, up 25% over the last three months. Envisagenics's team declined 11.9% over the past year.

Latest monthly visits1.5K 3-month web change+25% 1-year team growth-11.9%

Monthly website visitsJan 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GEGenialisCloud software for the visual exploration of next generation sequencing data	Boston, United States	Operational	33	$16M	$52M
TATurbine AISimulation-driven drug discovery company delivering population targeted cancer therapies	Budapest, Hungary	Operational
CTCelsius TherapeuticsSingle-cell RNA sequencing and genomic analysis	Cambridge, United States	Acquired
RPRecursion PharmaA clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery	Salt Lake City, United States	Operational
PEPepticomAn Artificial Intelligence (AI) company for the discovery of novel molecules in the Pharmaceutical and Agricultural markets	Jerusalem, Israel	Operational
SBSixfold BioscienceAI-powered programmable RNA delivery system for therapeutics.	London, United Kingdom	Operational
LILifebitEmpowers therapeutic leaders and pioneers in precision medicine on how to access and analyse siloed biomedical data	London, United Kingdom	Operational
IMInSilico MedicineDevelops an AI platform for drug development to treat cancer and age-related diseases	Cambridge, United States	Operational